Zentalis Pharmaceuticals (ZNTL) Payables (2019 - 2026)

Zentalis Pharmaceuticals' Payables history runs 8 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• In Q1 2026, Payables fell 5.03% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (down 5.03% YoY), while the FY2025 annual figure was $7.2 million, down 3.09% from the prior year.
• Payables for Q1 2026 stood at $7.4 million, up from $7.2 million in the prior quarter.
• The five-year high for Payables was $20.4 million in Q2 2024, with the low at $3.7 million in Q2 2025.
• The 5-year median for Payables is $10.5 million (2024), against an average of $10.6 million.
• The sharpest annual moves came in 2024 and 2025: Payables soared 66.11% in 2024, then plunged 81.81% in 2025.
• Zentalis Pharmaceuticals' Payables stood at $11.2 million in 2022, then jumped by 32.71% to $14.9 million in 2023, then slumped by 50.17% to $7.4 million in 2024, then declined by 3.09% to $7.2 million in 2025, then climbed by 2.36% to $7.4 million in 2026.
• Business Quant data shows ZNTL's Payables at $7.4 million in Q1 2026, $7.2 million in Q4 2025, and $7.0 million in Q3 2025.